Adjunct Treatment To Inhibit Renal Drug Excretion — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for adjunct treatment to inhibit renal drug excretion. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
5
Active US patents
76/100
Avg vulnerability
—
Annual revenue covered

Originators in Adjunct Treatment To Inhibit Renal Drug Excretion

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating adjunct treatment to inhibit renal drug excretion. Each bar = one year. Y-axis scaled to peak year (4 patents).

1
29
4
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Col-Probenecid
probenecid
 Pfizer Inc. 5 76 — 2029-06-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7795243 Col-Probenecid method of use 81 2029-06-03
12109197 Col-Probenecid method of use 75 2039-04-01
11554112 Col-Probenecid method of use 75 2039-04-01
12544337 Col-Probenecid method of use 75 2039-12-23
11478428 Col-Probenecid method of use 75 2039-12-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12544337 Col-Probenecid method of use 75 2039-12-23
11478428 Col-Probenecid method of use 75 2039-12-23
12109197 Col-Probenecid method of use 75 2039-04-01
11554112 Col-Probenecid method of use 75 2039-04-01
7795243 Col-Probenecid method of use 81 2029-06-03

Related